Swiss National Bank Buys 4,500 Shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS)
Swiss National Bank boosted its holdings in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 2.2% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 211,800 shares of the company’s stock after purchasing an additional 4,500 shares during the period. Swiss National Bank owned about 0.17% of Ionis Pharmaceuticals worth $10,654,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also modified their holdings of IONS. Ameriprise Financial Inc. boosted its holdings in Ionis Pharmaceuticals by 267.3% in the second quarter. Ameriprise Financial Inc. now owns 18,752 shares of the company’s stock valued at $953,000 after purchasing an additional 13,647 shares during the last quarter. Ark Investment Management LLC boosted its holdings in Ionis Pharmaceuticals by 38.7% in the second quarter. Ark Investment Management LLC now owns 176,991 shares of the company’s stock valued at $9,004,000 after purchasing an additional 49,428 shares during the last quarter. Parametric Portfolio Associates LLC boosted its holdings in Ionis Pharmaceuticals by 0.4% in the second quarter. Parametric Portfolio Associates LLC now owns 100,250 shares of the company’s stock valued at $5,100,000 after purchasing an additional 387 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Ionis Pharmaceuticals by 15.6% in the second quarter. Dimensional Fund Advisors LP now owns 196,812 shares of the company’s stock valued at $10,014,000 after purchasing an additional 26,496 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its holdings in Ionis Pharmaceuticals by 9.1% in the second quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock valued at $190,000 after purchasing an additional 311 shares during the last quarter. 90.95% of the stock is owned by hedge funds and other institutional investors.
In related news, SVP Patrick R. O’neil sold 645 shares of the stock in a transaction on Thursday, January 25th. The stock was sold at an average price of $55.00, for a total transaction of $35,475.00. Following the completion of the sale, the senior vice president now directly owns 15,097 shares in the company, valued at $830,335. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director B Lynne Parshall sold 5,986 shares of the stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $51.76, for a total value of $309,835.36. Following the sale, the director now owns 44,166 shares of the company’s stock, valued at $2,286,032.16. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 106,635 shares of company stock valued at $5,513,321. 2.13% of the stock is owned by corporate insiders.
Ionis Pharmaceuticals (NASDAQ:IONS) last posted its earnings results on Tuesday, February 27th. The company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.10. Ionis Pharmaceuticals had a negative return on equity of 1.94% and a negative net margin of 1.18%. The firm had revenue of $172.00 million for the quarter, compared to analysts’ expectations of $126.38 million. During the same period last year, the firm earned $0.33 EPS. The firm’s revenue was up 7.5% compared to the same quarter last year. equities analysts anticipate that Ionis Pharmaceuticals Inc will post -0.34 earnings per share for the current year.
IONS has been the topic of a number of research analyst reports. BidaskClub raised Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, December 7th. Zacks Investment Research downgraded Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, February 10th. Sanford C. Bernstein reiterated a “market perform” rating and set a $55.00 price target (down from $61.00) on shares of Ionis Pharmaceuticals in a research report on Tuesday, February 20th. Stifel Nicolaus increased their price target on Ionis Pharmaceuticals from $55.00 to $57.00 and gave the stock a “hold” rating in a research report on Wednesday, February 28th. Finally, BMO Capital Markets increased their price target on Ionis Pharmaceuticals from $64.00 to $65.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 28th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and seven have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $51.12.
COPYRIGHT VIOLATION NOTICE: This report was published by Marea Informative and is the sole property of of Marea Informative. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://www.mareainformativa.com/2018/03/16/swiss-national-bank-has-10-65-million-position-in-ionis-pharmaceuticals-inc-ions-updated-updated-updated.html.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.